Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity.
Chronic pain may result from hyperexcitability following activation of spinal NMDA receptors. A naturally-derived mammalian peptide, histogranin, may possess NMDA antagonist activity. This study explored the possibility that stable analog [Ser1]Histogranin (SHG) could reduce chronic pain. Neuropathic pain was induced using the chronic constriction injury model (CCI). Intrathecal injection of SHG markedly attenuated the hyperalgesia and allodynia resulting from CCI, nearly normalizing responses. These results suggest that the natural peptide histogranin may be a novel adjunct in neuropathic pain management.
Siegan
J B
JB
Department of Anatomy and Cell Biology, University of Illinois at Chicago, 60612, USA.
Hama
A T
AT
Sagen
J
J
D000818:Animals; D003864:Depression, Chemical; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D006930:Hyperalgesia / Q000188:drug therapy; D007278:Injections, Spinal; D008297:Male; D009437:Neuralgia / Q000188:drug therapy*; D059348:Peripheral Nerve Injuries; D011506:Proteins / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
D018691:Excitatory Amino Acid Antagonists; D011506:Proteins; D016194:Receptors, N-Methyl-D-Aspartate; C082312:histogranin